ES2900624T3 - Formulación de anticuerpos - Google Patents

Formulación de anticuerpos Download PDF

Info

Publication number
ES2900624T3
ES2900624T3 ES16162699T ES16162699T ES2900624T3 ES 2900624 T3 ES2900624 T3 ES 2900624T3 ES 16162699 T ES16162699 T ES 16162699T ES 16162699 T ES16162699 T ES 16162699T ES 2900624 T3 ES2900624 T3 ES 2900624T3
Authority
ES
Spain
Prior art keywords
formulation
antibody
formulations
acz885
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16162699T
Other languages
English (en)
Spanish (es)
Inventor
Joachim Momm
Hans-Joachim Wallny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2900624(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2900624T3 publication Critical patent/ES2900624T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES16162699T 2008-12-10 2009-12-09 Formulación de anticuerpos Active ES2900624T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation

Publications (1)

Publication Number Publication Date
ES2900624T3 true ES2900624T3 (es) 2022-03-17

Family

ID=40637230

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16162699T Active ES2900624T3 (es) 2008-12-10 2009-12-09 Formulación de anticuerpos
ES09764858.8T Active ES2579835T3 (es) 2008-12-10 2009-12-09 Formulación de anticuerpo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09764858.8T Active ES2579835T3 (es) 2008-12-10 2009-12-09 Formulación de anticuerpo

Country Status (31)

Country Link
US (3) US20110236398A1 (show.php)
EP (4) EP2196476A1 (show.php)
JP (6) JP6143416B2 (show.php)
KR (2) KR20170044211A (show.php)
CN (3) CN104399076B (show.php)
AU (1) AU2009324371B2 (show.php)
BR (1) BRPI0922730A2 (show.php)
CA (1) CA2745938C (show.php)
CL (1) CL2011001406A1 (show.php)
CO (1) CO6361952A2 (show.php)
CY (2) CY1117735T1 (show.php)
DK (2) DK3072906T3 (show.php)
EC (1) ECSP11011192A (show.php)
ES (2) ES2900624T3 (show.php)
HR (2) HRP20160754T1 (show.php)
HU (2) HUE028408T2 (show.php)
IL (3) IL264316B2 (show.php)
LT (1) LT3072906T (show.php)
MA (1) MA33023B1 (show.php)
MX (1) MX2011006242A (show.php)
MY (2) MY157772A (show.php)
NZ (1) NZ592918A (show.php)
PE (1) PE20120342A1 (show.php)
PL (2) PL3072906T3 (show.php)
PT (2) PT2376533T (show.php)
RU (2) RU2745601C2 (show.php)
SI (2) SI2376533T1 (show.php)
SM (1) SMT201600222B (show.php)
TN (1) TN2011000229A1 (show.php)
WO (1) WO2010066762A1 (show.php)
ZA (1) ZA201103362B (show.php)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
SMT201700454T1 (it) 2010-03-01 2018-01-11 Bayer Healthcare Llc Anticorpi monoclonali ottimizzati contro inibitore della via di fattore tissutale (tfpi)
HRP20241526T1 (hr) 2010-05-28 2025-01-03 Novo Nordisk A/S Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EA027353B1 (ru) 2010-09-17 2017-07-31 Баксалта Инкорпорейтид СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
SMT202200321T1 (it) 2010-10-01 2022-09-14 Modernatx Inc Acidi ribonucleici contenenti n1-metil-pseudouracili e loro usi
TWI700093B (zh) 2011-03-16 2020-08-01 法商賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
CN104302171B (zh) * 2012-03-16 2017-05-03 瑞泽恩制药公司 表达ph敏感性免疫球蛋白序列的非人动物
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CN104995210A (zh) 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
WO2014078502A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AR095496A1 (es) 2013-03-15 2015-10-21 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
US10206878B2 (en) * 2014-05-28 2019-02-19 Nono Inc. Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
CN106604744A (zh) * 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EA201891339A1 (ru) 2015-12-07 2019-01-31 Мерк Патент Гмбх Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
HRP20210945T1 (hr) * 2016-06-27 2021-09-17 Morphosys Ag Formulacije protutijela anti-cd19
KR20190032436A (ko) * 2016-07-21 2019-03-27 노파르티스 아게 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도
EP3518891A1 (en) * 2016-09-27 2019-08-07 Fresenius Kabi Deutschland GmbH Liquid pharmaceutical composition
US10517966B2 (en) 2016-11-18 2019-12-31 Astellas Pharma Inc. Anti-human MUC1 antibody Fab fragment
US20190048072A1 (en) * 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
AU2018333106A1 (en) * 2017-09-13 2020-04-02 Novartis Ag Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
CN112004827A (zh) * 2018-03-23 2020-11-27 艾伯维德国有限责任两合公司 稳定的水性抗tau抗体调配物
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
UA128098C2 (uk) 2019-02-18 2024-04-03 Елі Ліллі Енд Компані Водна фармацевтична композиція антитіла проти il-17a
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
WO2022135395A1 (zh) * 2020-12-22 2022-06-30 百奥泰生物制药股份有限公司 稳定的抗体制剂及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2002002773A2 (en) * 2000-06-29 2002-01-10 Abbott Laboratories Dual specificity antibodies and methods of making and using
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
AR062247A1 (es) * 2005-03-08 2008-10-29 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti-ctla-4
WO2006125207A2 (en) * 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
KR20170038131A (ko) 2005-10-26 2017-04-05 노파르티스 아게 Ｉｌ-1베타 화합물의 신규 용도
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
RU2009126420A (ru) * 2006-12-11 2011-01-20 Ф.Хоффманн-Ля Рош Аг (Ch) Парентеральная лекарственная форма антитела к абета
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
KR101762966B1 (ko) 2017-07-31
JP2012511540A (ja) 2012-05-24
JP7286595B2 (ja) 2023-06-05
MA33023B1 (fr) 2012-02-01
CN114225022A (zh) 2022-03-25
LT3072906T (lt) 2021-12-27
CY1124844T1 (el) 2022-11-25
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
CN104399076B (zh) 2021-09-14
MX2011006242A (es) 2011-06-24
WO2010066762A1 (en) 2010-06-17
CY1117735T1 (el) 2017-05-17
TN2011000229A1 (en) 2012-12-17
DK3072906T3 (da) 2021-12-13
US20110236398A1 (en) 2011-09-29
DK2376533T3 (en) 2016-06-27
PE20120342A1 (es) 2012-04-24
IL264316B2 (en) 2024-01-01
IL212922A0 (en) 2011-07-31
SMT201600222B (it) 2016-08-31
EP3792282A1 (en) 2021-03-17
RU2745601C2 (ru) 2021-03-29
CO6361952A2 (es) 2012-01-20
EP3072906A1 (en) 2016-09-28
IL264316B1 (en) 2023-09-01
EP3072906B1 (en) 2021-09-08
IL212922B (en) 2019-02-28
AU2009324371B2 (en) 2013-10-10
US20200384108A1 (en) 2020-12-10
BRPI0922730A2 (en) 2018-11-06
HRP20211899T1 (hr) 2022-03-04
JP2015231997A (ja) 2015-12-24
RU2563179C2 (ru) 2015-09-20
ECSP11011192A (es) 2011-08-31
PT2376533T (pt) 2016-07-13
JP2018168158A (ja) 2018-11-01
SI2376533T1 (sl) 2016-07-29
PT3072906T (pt) 2021-12-14
IL264316A (en) 2019-02-28
MY166050A (en) 2018-05-22
CN104399076A (zh) 2015-03-11
EP2376533A1 (en) 2011-10-19
HK1159130A1 (zh) 2012-07-27
PL2376533T3 (pl) 2016-09-30
RU2011127913A (ru) 2013-01-20
PL3072906T3 (pl) 2022-01-24
HRP20160754T1 (hr) 2016-08-12
KR20170044211A (ko) 2017-04-24
HUE028408T2 (en) 2016-12-28
ES2579835T3 (es) 2016-08-17
CN102245639A (zh) 2011-11-16
RU2015132431A (ru) 2018-12-24
CA2745938C (en) 2018-04-24
CN102245639B (zh) 2014-12-24
US8623367B2 (en) 2014-01-07
US20120315285A1 (en) 2012-12-13
CA2745938A1 (en) 2010-06-17
JP6143416B2 (ja) 2017-06-07
JP2026021446A (ja) 2026-02-10
AU2009324371A1 (en) 2011-06-23
ZA201103362B (en) 2012-01-25
IL276622A (en) 2020-09-30
HUE056626T2 (hu) 2022-02-28
CL2011001406A1 (es) 2012-03-30
SI3072906T1 (sl) 2022-01-31
EP2196476A1 (en) 2010-06-16
EP2376533B1 (en) 2016-03-30
KR20120009421A (ko) 2012-01-31
JP2020203889A (ja) 2020-12-24
RU2015132431A3 (show.php) 2018-12-24
JP2023109938A (ja) 2023-08-08

Similar Documents

Publication Publication Date Title
ES2900624T3 (es) Formulación de anticuerpos
ES2974895T3 (es) Formulación líquida que comprende un compuesto neutralizante de GM-CSF
CA2866692A1 (en) Formulations which prevent formation of antibody aggregates
US9833410B2 (en) Lyophilized formulation comprising GM-CSF neutralizing compound
CN104740609A (zh) 一种受体抗体融合蛋白的药物组合物
HK40041917A (en) Antibody formulation
HK1159130B (en) Antibody formulation
CN116685309A (zh) 改善的冻干制剂
ES2794449T3 (es) Formulación líquida que comprende un compuesto neutralizante del GM-CSF